



2021-2022 BOARD OF DIRECTORS

President
Daniel P. McQuillen, M.D., FIDSA
BETH ISRAEL LAHEY HEALTH
LAHEY HOSPITAL & MEDICAL CENTER
BURLINGTON, MA

President-Elect
Carlos Del Rio, M.D., FIDSA
EMORY SCHOOL OF MEDICINE AT
GRADY HEALTH SYSTEM
ATLANTA, GA

Vice President
Steven K. Schmitt, M.D., FIDSA
CLEVELAND CLINIC
CLEVELAND, OH

Secretary
Angela M. Caliendo, M.D., Ph.D., FIDSA
ALPERT MEDICAL SCHOOL OF BROWN UNIVERSITY
RHODE ISLAND HOSPITAL
PROVIDENCE, RI

Treasurer
Jeanne Mrazzoz, M.D., MPH, FIDSA
UNIVERSITY OF ALABAMA AT BIRMINGHAM
SCHOOL OF MEDICINE
BIRMINGHAM, AL

Immediate Past President
Barbara D. Alexander, M.D., MHS, FIDSA
DUKE UNIVERSITY
DURHAM, NC

Lilian M. Abbo, M.D., FIDSA
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
MIAMI, FL

Adaora A. Adimora, M.D., MPH, FIDSA
UNIVERSITY OF NORTH CAROLINA SCHOOL
OF MEDICINE
CHAPEL HILL, NC

Cesar A. Arias, M.D., Ph.D., FIDSA
HOUSTON METHODIST HOSPITAL
HOUSTON, TX

Wendy Armstrong, M.D., FIDSA
EMORY UNIVERSITY
ATLANTA, GA

Maximo O. Brito, M.D., MPH, FIDSA
UNIVERSITY OF ILLINOIS AT CHICAGO
CHICAGO, IL

Rana Chakraborty, M.D., MSc, D.Phil., FIDSA
MAYO CLINIC
ROCHESTER, MN

Kimberly E. Hanson, M.D., FIDSA
UNIVERSITY OF UTAH
SALT LAKE CITY, UT

John B. Lynch, III, M.D., MPH, FIDSA
HARBORVIEW MEDICAL CENTER
UNIVERSITY OF WASHINGTON
SEATTLE, WA

Jasmine R. Marcelin, M.D., FIDSA
UNIVERSITY OF NEBRASKA MEDICAL CENTER
OMAHA, NE

Chief Executive Officer
Christopher D. Busky, CAE

IDSAs Headquarters
4040 Wilson Boulevard
Suite 300
Arlington, VA 22203
TEL: (703) 299-0200
FAX: (703) 299-0204
EMAIL ADDRESS:
info@idsociety.org
WEBSITE:
www.idsociety.org

The Honorable Richard Blumenthal
United States Senate
706 Hart Office Building
Washington, DC 20510

The Honorable Roger Marshall
United States Senate
479A Russell Office Building
Washington, DC 20510

August 26, 2022

Dear Senators Blumenthal and Marshall,

On behalf of IDSAs's 12,000 members, including our 115 members in Connecticut and our 40 members in Kansas, thank you for your leadership in the federal response to antimicrobial resistance (AMR). IDSAs is extremely grateful that your efforts, particularly your letter signed by 22 of your colleagues, resulted in increases for AMR programs in the FY2023 Labor, Health, and Human Services (LHHS) appropriation bill released by the Senate Appropriations Committee, outlined below.

As you know, AMR is rendering lifesaving medicines ineffective thereby jeopardizing medical procedures that rely upon antibiotics. These include cancer chemotherapy, transplantation, caesarian sections, other surgeries, treatment of serious wounds and burns and care of complex patients — such as individuals with COVID-19 who develop secondary infections. Infectious diseases physicians see firsthand the impact of the growing AMR crisis on our patients, communities and public health, and agree that increased efforts are urgently needed to preserve the effectiveness of antibiotics and strengthen the pipeline of new antibiotics. Increased AMR funding in the LHHS bill released by the committee will expand AMR research and strengthen the antibiotic pipeline and would not have been possible without your leadership. Thank you for your steadfast efforts to expand our capacity to combat AMR to better care for our patients and communities.

Sincerely,

Daniel P. McQuillen, MD, FIDSA
President, Infectious Diseases Society of America

AMR program funding in the Senate LHHS appropriations bill:

- \$212 million for the **CDC's Antibiotic Resistance Solutions Initiative**, a \$30 million increase over FY2022;
- \$31 million in funding for the **National Healthcare Safety Network at CDC**, a \$10 million increase over FY2022;
- \$50 million in funding for the **Advanced Molecular Detection initiative at CDC**, a \$15 million increase over FY2022;
- \$760 million in funding, an increase of \$114 million above FY 2022, for the **CDC's Center for Global Health**. This includes \$353 million for global health security, a \$100 million increase;
- \$818 million for the **Biomedical Advanced Research and Development Authority**, a \$73.5 million increase over FY 2022 funding; and,
- \$6.449 billion for the **National Institute of Allergy and Infectious Diseases at the National Institutes of Health**, a \$127 million increase over FY 2022, including \$565 million for antibiotic resistance research at NIAID, an increase of \$25 million over FY 2022;